组蛋白修饰在口腔鳞状细胞癌中的研究进展

doi:10.13591/j.cnki.kqyx.2022.07.015

摘要/Abstract

摘要： 口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)是口腔颌面部最常见的恶性肿瘤,而OSCC患者就诊时往往疾病已发展到晚期阶段并出现肿瘤转移,导致预后不佳。OSCC的发病机制尚不清楚,目前早期有效监测OSCC发生、侵袭、转移及复发的分子靶点仍需要进一步探究。当前的研究显示,各种组蛋白修饰改变了染色质结构,进而影响相关下游基因的转录活性,调控基因表达水平,在OSCC的生物学检测、病理分级与分期、预后判断中均发挥重要作用。该文主要对组蛋白的甲基化、乙酰化、磷酸化、泛素化、二磷酸腺苷核糖基化等修饰在OSCC中的研究进展进行综述。

关键词: 口腔鳞状细胞癌, 组蛋白修饰, 标志物, 靶向治疗

Abstract: Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the oral and maxillofacial region, but when OSCC patients seek medical advice, the disease has often reached an advanced stage and tumor metastasis has appeared, resulting in a poor prognosis. Its pathogenesis is still unclear, and there is still demand for effective diagnostic and therapeutic targets to monitor the invasion, metastasis and recurrence of OSCC. Studies show that histone modification changes chromatin structure, thereby affecting transcriptional activity of related downstream genes and regulating gene expression levels, which plays an important role in biological detection, pathological grading and staging, prognosis of OSCC. This article reviews current research progress of histone modification including methylation, acetylation, phosphorylation, ubiquitination and ADP-ribosylation in oral squamous cell carcinoma.

Key words: oral squamous cell carcinoma, histone modification, biomarker, molecular targeted therapy

中图分类号:

R739.85

侯伊明, 李娜, 禹文茜, 陈磊. 组蛋白修饰在口腔鳞状细胞癌中的研究进展[J]. 口腔医学, 2022, 42(7): 650-654.

HOU Yiming, LI Na, YU Wenqian, CHEN Lei. Research progress of histone modification in oral squamous cell carcinoma[J]. Stomatology, 2022, 42(7): 650-654.

参考文献

[1] Johnson DE,Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1):92.
[2] Olino K, Park T, Ahuja N. Exposing Hidden Targets:Combining epigenetic and immunotherapy to overcome cancer resistance[J]. Semin Cancer Biol, 2020, 65:114-122.
[3] Romanowska K, Sobecka A, Rawłuszko-Wieczorek AA, et al. Head and neck squamous cell carcinoma:Epigenetic landscape[J]. Diagnostics (Basel), 2020, 11(1):E34.
[4] Yamamoto T,Hirosue A, Nakamoto M, et al. BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene[J]. Br J Cancer, 2020, 123(4):580-590.
[5] Zhao S, Allis CD, Wang GG. The language of chromatin modification in human cancers[J]. Nat Rev Cancer, 2021, 21(7):413-430.
[6] Li YL, Chen X, Lu C. The interplay between DNA and histone methylation:Molecular mechanisms and disease implications[J]. EMBO Rep, 2021, 22(5):e51803.
[7] Gasche JA, Goel A. Epigenetic mechanisms in oral carcinogenesis[J]. Futur Oncol Lond Engl, 2012, 8(11):1407-1425.
[8] Maia LL,Peterle GT, dos Santos M, et al. JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma[J]. PLoS One, 2018, 13(3):e0194884.
[9] Sant'Ana JMA, Servato JPS, Matsuo FS, et al. The role of the histones H3K9ac, H3K9me3, HP1γ, and H3K36me3 in oral squamous cell carcinoma loco-regional metastasis and relapse[J]. Pathol Res Pract, 2020, 216(11):153201.
[10] Chen YW, Kao SY, Wang HJ,et al. Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma[J]. Cancer, 2013, 119(24):4259-4267.
[11] Yuan CP, Li ZW, Qi B, et al. High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer[J]. J Oral Pathol Med, 2015, 44(2):159-165.
[12] Jin X,Xu H, Wu XY, et al. KDM4A as a prognostic marker of oral squamous cell carcinoma:Evidence from tissue microarray studies in a multicenter cohort[J]. Oncotarget, 2017, 8(46):80348-80357.
[13] Ratovitski EA. Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas[J]. Cell Cycle, 2014, 13(5):749-761.
[14] Facompre ND, Harmeyer KM, Sole X, et al. JARID1B enables transit between distinct states of the stem-like cell population in oral cancers[J]. Cancer Res, 2016, 76(18):5538-5549.
[15] Huang DH,Qiu YZ, Li G, et al. KDM5B overexpression predicts a poor prognosis in patients with squamous cell carcinoma of the head and neck[J]. J Cancer, 2018, 9(1):198-204.
[16] Lin CS, Lin YC, Adebayo BO, et al. Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma[J]. Cancer Lett, 2015, 368(1):36-45.
[17] Chen YH, Chen CH, Chien CY, et al. Overexpression of UTX promotes tumor progression in Oral tongue squamous cell carcinoma patients receiving surgical resection:A case control study[J]. BMC Cancer, 2021, 21(1):979.
[18] Guan ZH,Giustetto M, Lomvardas S, et al. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure[J]. Cell, 2002, 111(4):483-493.
[19] Li QH, Sun HY,Shu Y, et al. hMOF (human males absent on the first), an oncogenic protein of human oral tongue squamous cell carcinoma, targeting EZH2 (enhancer of zeste homolog 2)[J]. Cell Prolif, 2015, 48(4):436-442.
[20] Giudice FS, Pinto DS Jr, Nör JE, et al. Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer[J]. PLoS One, 2013, 8(3):e58672.
[21] Kusumoto T, Hamada T, Yamada N, et al. Comprehensive epigenetic analysis using oral rinse samples:A pilot study[J]. J Oral Maxillofac Surg, 2012, 70(6):1486-1494.
[22] Webber LP, Wagner VP,Curra M, et al. Hypoacetylation of acetyl-histone H3 (H3K9ac) as marker of poor prognosis in oral cancer[J]. Histopathology, 2017, 71(2):278-286.
[23] Arif M, Vedamurthy BM, Choudhari R, et al. Nitric oxide-mediated histone hyperacetylation in oral cancer:Target for a water-soluble HAT inhibitor, CTK7A[J]. Chem Biol, 2010, 17(8):903-913.
[24] Witt O, Deubzer HE, Milde T, et al. HDAC family:What are the cancer relevant targets?[J]. Cancer Lett, 2009, 277(1):8-21.
[25] Theocharis S, Klijanienko J, Giaginis C, et al. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma:Associations with clinicopathological parameters and patients survival[J]. J Oral Pathol Med, 2011, 40(9):706-714.
[26] Sakuma T, Uzawa K, Onda T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma[J]. Int J Oncol, 2006, 29(1):117-124.
[27] Ahn MY, Yoon JH. Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma[J]. Oncol Rep, 2017, 37(1):540-546.
[28] Rastogi B, Raut SK, Panda NK, et al. Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis[J]. Mol Cell Biochem, 2016, 415(1/2):183-196.
[29] Chang CC, Lin BR, Chen ST,et al. HDAC2 promotes cell migration/invasion abilities through HIF-1α stabilization in human oral squamous cell carcinoma[J]. J Oral Pathol Med, 2011, 40(7):567-575.
[30] Baek SH. When signaling kinases meet histones and histone modifiers in the nucleus[J]. Mol Cell, 2011, 42(3):274-284.
[31] Lee JW,Parameswaran J, Sandoval-Schaefer T, et al. Combined aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck[J]. Clin Cancer Res, 2019, 25(11):3430-3442.
[32] Pannone G, Hindi SA, Santoro A, et al. Aurora B expression as a prognostic indicator and possible therapeutic target in oral squamous cell carcinoma[J]. Int J Immunopathol Pharmacol, 2011, 24(1):79-88.
[33] Qi GY, Ogawa I,Kudo Y, et al. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer[J]. Virchows Arch, 2007, 450(3):297-302.
[34] Huber GF,Albinger-Hegyi A, Soltermann A, et al. Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma[J]. Cancer, 2011, 117(20):4659-4670.
[35] Chen DM, Wu MS, Li Y,et al. Targeting BMI1⁺ cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma[J]. Cell Stem Cell, 2017, 20(5):621-634.e6.
[36] Paul A, Wang B. RNF^8- and Ube2S-dependent ubiquitin lysine 11-linkage modification in response to DNA damage[J]. Mol Cell, 2017, 66(4):458-472.e5.
[37] Yoshimura S,Kasamatsu A, Nakashima D, et al. UBE2S associated with OSCC proliferation by promotion of P21 degradation via the ubiquitin-proteasome system[J]. Biochem Biophys Res Commun, 2017, 485(4):820-825.
[38] Liu T, Liu J, Chen QY,et al. Expression of USP22 and the chromosomal passenger complex is an indicator of malignant progression in oral squamous cell carcinoma[J]. Oncol Lett, 2019, 17(2):2040-2046.
[39] Liu XY, Kumar M, Yang LP,et al. BAP1 is a novel target in HPV-negative head and neck cancer[J]. Clin Cancer Res, 2018, 24(3):600-607.
[40] Das BR. Increased ADP-ribosylation of histones in oral cancer[J]. Cancer Lett, 1993, 73(1):29-34.
[41] Yasukawa M,Fujihara H, Fujimori H, et al. Synergetic effects of PARP inhibitor AZD2281 and cisplatin in oral squamous cell carcinoma in vitro and in vivo[J]. Int J Mol Sci, 2016, 17(3):272.
[42] Molla S, Hembram KC, Chatterjee S, et al. PARP inhibitor olaparib enhances the apoptotic potentiality of curcumin by increasing the DNA damage in oral cancer cells through inhibition of BER cascade[J]. Pathol Oncol Res, 2020, 26(4):2091-2103.